[1]吴嘉慧,胡荣.从荟萃分析结果看新型口服抗凝药物在心房颤动卒中预防中的获益[J].国际心血管病杂志,2016,04:204-206.
点击复制
从荟萃分析结果看新型口服抗凝药物在心房颤动卒中预防中的获益(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2016年04期
- 页码:
- 204-206
- 栏目:
- 综述
- 出版日期:
- 2016-07-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2016.04.004
- 文献标识码:
- -
- 摘要:
- 抗凝治疗在非瓣膜病性心房颤动(房颤)患者的卒中预防中起关键作用。荟萃分析结果提示,在非瓣膜性房颤患者中,新型口服抗凝药物与华法林相比风险获益比更佳,卒中风险、颅内出血风险及死亡率均显著降低。不同的新型口服抗凝药物的药代动力学及分子机制差异可能显著影响药物在特定人群如老年人、肾功能不全人群中的作用,临床医师应选择个性化治疗方案,平衡血栓和出血风险,尽可能达到最佳的风险获益平衡。
- Abstract:
- -
参考文献/References
[1] Schulman S. New anticoagulants in atrial fibrillation management [J]. Thromb Res, 2013,131(Suppl 1):S63-66.
[2] Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association [J]. Eur Heart J, 2012,33(21):2719-2747.
[3] Perez A, Eraso LH, Merli GJ. Implications of new anticoagulants in primary practice [J]. Int J Clin Pract, 2013,67(2):139-156.
[4] Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients [J]. Int J Cardiol, 2013,167(4):1237-1241.
[5] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2009,361(12):1139-1151.
[6] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [J]. N Engl J Med,2011,365(10):883-891.
[7] Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation [J]. N Engl J Med,2011, 365(11): 981-992.
[8] Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials [J]. Lancet,2014,383(9921):955-962.
[9] Senoo K, Lau YC, Dzeshka M, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation [J]. Circ J,2015,79(2):339-345.
[10] Fu W, Guo H, Guo J, et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis [J]. J Cardiovasc Med(Hagerstown),2014,15(12):873-879.
[11] Mitchell SA, Simon TA, Raza S, et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis [J]. Clin Appl Thromb Hemost,2013,19(6):619-631.
[12] Touma L, Filion KB, Atallah R, et al. A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists [J]. Am J Cardiol, 2015,115(4):533-541.
[13] Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation [J]. N Engl J Med, 2011,364(9):806-817.
[14] Loffredo L, Perri L, Violi F. Myocardial infarction and atrial fibrillation: Different impact of anti-IIa vs anti-Xa new oral anticoagulants: A meta-analysis of the interventional trials [J]. Int J Cardiol, 2015,178(1):8-9.
[15] Rui P, Erik Lerkevang G, Steen H, et al. A meta-analysis of phase Ⅲ randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens [J]. Thromb Res, 2014,134(6):1253-1264.
[16] Verdecchia P, Angeli F, Bartolini C, et al. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach [J]. Expert Opin Drug Saf, 2015,14(1):7-20.
[17] Sardar P, Chatterjee S, Herzog E, et al. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials [J]. Can J Cardiol, 2014,30(8):888-897.
[18] Pathak R, Pandit A, Karmacharya P, et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment [J]. Am J Cardiol, 2015,115(3):323-327.
[19] Guo Y, Tian Y, Wang H, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation [J]. Chest, 2015,147(1):109-119.
[20] 温志超,李 剑,罗心平. 欧洲心脏病学会2012年心房颤动指南更新摘要 [J]. 国际心血管病杂志, 2012, 39(6): 327-328.
[21] 中华医学会心血管病学分会,中国医师协会心律学专业委员会. 非瓣膜病心房颤动患者新型口服抗凝药的应用中国专家共识 [J]. 中华心律失常学杂志, 2014, 18(5): 321-329.
备注/Memo
- 备注/Memo:
- 通信作者:胡 荣,Email:huronggg@126.com
常用功能
统计/Statistics
- 摘要浏览/Viewed1
- 全文下载/Downloads958
- 评论/Comments
